Table 1.

Continuous in vivo exposure to ES-62 does not reduce the recovery of splenic B cells or modulate the relative proportions of lymphocyte populations^*

Cell type	PBS	ES-62 (0·05 µg/hr)	ES-62 (0·2 µg/hr)
B220	50·2 ± 7·7	42·4 ± 12·0	43·9 ± 10·4
CD3	29·6 ± 1·8	31·5 ± 2·3	31·9 ± 11·4
CD4	21·9 ± 4·7	21·1 ± 8·6	22·7 ± 12·0
CD8	7·7 ± 0·3	8·5 ± 2·0	8·1 ± 1·9

^*Cell counts following sacrifice demonstrated no significant differences in the numbers of cells recovered between PBS and ES-62 treatments and indicated that in vivo exposure to ES-62 did not reduce splenic cellularity. In three experiments using five mice per group, post-death spleen cell counts (mean ± SD) were PBS: 142 ± 38 × 10⁶; ES-62 (0·05 µg/hr): 123 ± 27 × 10⁶ and ES-62 (0·2 µg/hr): 143 ± 7 × 10⁶. Determination of the percentage of individual lymphocyte populations by lineage marker analysis demonstrated that relative cell proportions remained unchanged and that B cell numbers recovered were essentially identical in control and ES-62 treated groups. Data are presented as the percentage of cells (mean ± SD, n = 4 independent experiments) and there were no significant differences amongst any of the groups.